Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2033

Annual patent cliff calendar for 2033 — US pharmaceutical patents by expiration date.

Patents
1,330

Quick answer

1,330 indexed pharmaceutical patents have expiration dates in 2033. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 8426461

    Orally dispersible tablet

    Takeda Pharmaceutical Company Limited · Granted Tue Apr 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8426365

    Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure

    REGENERX BIOPHARMACEUTICALS, INC. · Granted Tue Apr 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8426379

    POT1 alternative splicing variants

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8426414

    Modulators of G protein-coupled receptor 88

    LEXICON PHARMACEUTICALS, INC. · Granted Tue Apr 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8426432

    Inhibitors of dihydrofolate reductase with antibacterial antiprotozoal, antifungal and anticancer properties

    UNIVERSITY OF CONNECTICUT · Granted Tue Apr 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8426426

    Gyrase inhibitors and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Tue Apr 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8426554

    In vivo polynucleotide delivery conjugates having enzyme sensitive linkages

    Arrowhead Madison, Inc. · Granted Tue Apr 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8426597

    Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases

    CARDIOLYNX AG · Granted Tue Apr 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8426585

    Compounds comprising a spiro-ring

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Tue Apr 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8426611

    7-azoniabicyclo[2.2.1]heptane derivatives, methods of production, and pharmaceutical uses thereof

    THERON PHARMACEUTICALS, INC. · Granted Tue Apr 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. CA 2852397

    UTILISATION DE GLYCOSAMINOGLYCANES SULFATES POUR AMELIORER LA BIODISPONIBILITE DU FACTEUR VIII

    CSL BEHRING GMBH [DE] · Granted Thu Apr 25 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 20 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. CA 2851057

    UTILISATION COMBINEE D'UN GLYCOSAMINOGLYCANE SULFATE ET D'UNE HYALURONIDASE POUR AMELIORER LA BIODISPONIBILITE DU FACTEUR VIII

    CSL BEHRING GMBH [DE] · Granted Thu Apr 25 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 20 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8430832

    Selective cytopheresis devices and related methods thereof

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8431543

    Chitosan based polymer conjugate and a method for producing the same

    ENGENE, INC. · Granted Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8431124

    Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP)

    HALOZYME, INC. · Granted Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8431134

    Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen

    The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention · Granted Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8431116

    Norovirus vaccine formulations

    Takeda Vaccines (Montana), Inc. · Granted Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8431154

    Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient

    TAKEDA GMBH · Granted Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8431605

    Modulators of ATP-binding cassette transporters

    Vertex Pharmaceuticals Incorporated · Granted Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8431176

    Liquid chromatographic fraction of enzymatically polymerized flavonoid as an antioxidant

    The United States of America as represented by the Secretary of the Army · Granted Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8431380

    Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof

    HALOZYME, INC. · Granted Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8431558

    Compositions and methods for modification of biomolecules

    The Regents of the University of California · Granted Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8431561

    Methods and compositions for treatment of excess nitric oxide or cyanide toxicity

    The Regents of the University of California · Granted Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8431690

    T cell receptors and related materials and methods of use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8431594

    Bridged bicyclic heteroaryl substituted triazoles useful as AXL inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8431566

    Cyclopamine lactam analogs and methods of use thereof

    Infinity Discovery, Inc. · Granted Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8431615

    Dose forms

    Vertex Pharmaceuticals Incorporated · Granted Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8431626

    Disulfide monomers comprising ethylenically unsaturated norbornyl groups suitable for dental compositions

    The Regents of the University of Colorado · Granted Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8431556

    C-21-keto lupane derivatives preparation and use thereof

    Vertex Pharmaceuticals Incorporated · Granted Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8431570

    Methods of utilizing arylpiperazine derivatives

    REVIVA PHARMACEUTICALS, INC. · Granted Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8431532

    FZD8 extracellular domains and FZD8 extracellular domain fusion molecules and treatments using same

    Five Prime Therapeutics, Inc. · Granted Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. AU 2012205809

    Phenethylsulfone isoindoline derivatives as inhibitors of PDE 4 and/or cytokines

    CELGENE CORP [CH] · Granted Thu May 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 27 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8436224

    Methods for testing for caloric restriction (CR) mimetics

    BioMarker Pharmaceuticals, Inc. · Granted Tue May 07 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8435497

    Formoterol of and ciclesonide combination

    TAKEDA GMBH · Granted Tue May 07 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8435505

    Pharmaceutical compositions and methods for delivering such compositions

    Nektar Therapeutics · Granted Tue May 07 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8435570

    Nitrite formulations and their use as nitric oxide prodrugs

    The Board of Regents of the University of Texas System · Granted Tue May 07 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8436014

    Solid forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluorormethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihyroquinoline-3-carboxamide

    Vertex Pharmaceuticals Incorporated · Granted Tue May 07 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8435979

    Use of imipramine blue and analogs thereof in treating cancers

    The United States of America as Represented by the Dept. of Veterans Affairs · Granted Tue May 07 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8435995

    Pyridazinone compounds

    Takeda Pharmaceutical Company Limited · Granted Tue May 07 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8435960

    Devices for improved wound management

    Lakewood Amedex, Inc. · Granted Tue May 07 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8435533

    Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of Chlamydia

    The Board of Regents of the University of Texas System · Granted Tue May 07 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8435575

    Use of gingerols for cancer patients suffering from nausea and emesis induced by chemotherapy

    Aphios Corporation · Granted Tue May 07 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8435941

    Mini-hepcidin peptides and methods of using thereof

    The Regents of the University of California · Granted Tue May 07 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8436154

    Crystallizing method of erythromycin

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Tue May 07 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8436043

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Tue May 07 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8436200

    Process for making (R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-flouro-4- iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione and intermediates thereof

    Takeda Pharmaceutical Company Limited · Granted Tue May 07 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8436187

    1-heterocyclylsulfonyl, 3-aminomethyl, 5- (hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors

    Takeda Pharmaceutical Company Limited · Granted Tue May 07 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8435507

    Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer

    The United States of America as Represented by the Dept. of Veterans Affairs · Granted Tue May 07 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2033?

1,330 published patents in our USPTO index have expiration dates falling in calendar year 2033.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.